Table 2.

Means and Standard Deviations of Modeled Variables

Variable	Residential (N=476)	Outpatient (N=519)
SPI
Baseline	5.38 (4.89)	3.76 (3.42)
3-month	2.53 (3.93)	2.46 (3.20)
6-month	2.31 (3.84)	2.18 (3.10)
9-month	2.83 (4.07)	1.96 (2.97)
12-month	2.62 (4.10)	1.83 (2.72)
TX dose*
Baseline	0.31 (0.65)	0.23 (.70)
3-month	2.30 (0.93)	1.68 (.65)
6-month	1.14 (1.40)	0.36 (.86)
9-month	0.70 (1.15)	0.37 (.92)
12-month	0.51 (1.08)	0.30 (.86)
LSE
Baseline	0.33 (0.29)	0.20 (0.22)
3-month	0.30 (0.27)	0.19 (0.23)
6-month	0.29 (0.27)	0.17 (0.21)
9-month	0.28 (0.27)	0.18 (0.22)
12-month	0.26 (0.26)	0.16 (0.21)
PNT
Baseline	0.56 (0.31)	0.50 (0.28)
3-month	0.53 (0.31)	0.40 (0.29)
6-month	0.46 (0.31)	0.35 (0.28)
9-month	0.45 (0.31)	0.36 (0.30)
12-month	0.44 (0.31)	0.36 (0.29)

^*Note: Residential and outpatient samples are measured on different scales.

SPI, substance-use problem index; LSE, low drug-resistance self-efficacy; PNT, perceived need for treatment.